GlassScriptPhysician profile
Xiang D Dong
NPI 1912970435
$4,747.99
in general payments reported to CMS, 2019-2025
46 companies · $1,941 in 2025
The $1,941 reported for 2025 was more than what 81% of Surgical Oncology providers received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $802 · 2021: $291 · 2022: $540 · 2023: $394 · 2024: $780 · 2025: $1,941.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,218 · Travel and Lodging: $897.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,218.36 |
| Travel and Lodging | $897.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Histosonics, INC. | $1,168.06 | 2025 | |
| Allergan, INC. | $371.75 | 2019 | |
| Medtronic, INC. | $359.19 | 2021-2025 | Signia, Maxtack, Pteye Parathyroid Detection System |
| Astrazeneca Pharmaceuticals LP | $272.29 | 2021-2024 | Tagrisso, Lynparza, Enhertu |
| Novartis Pharmaceuticals Corporation | $198.43 | 2022-2025 | |
| Eisai INC. | $190.89 | 2022-2025 | |
| Tei Biosciences INC | $185.53 | 2019 | |
| Rigel Pharmaceuticals, INC. | $156.23 | 2024-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Boston Scientific Corporation | $140.89 | 2024 | Spyglass Discover |
| Ethicon US, LLC | $135.11 | 2019-2025 | Harmonic, Echelon Circular, Echelon Flex |
| Merck Sharp & Dohme LLC | $134.24 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Kerecis Limited | $120.25 | 2023-2025 | Kerecis Surgiclose, Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen |
| Integra Lifesciences Corporation | $98.48 | 2024-2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Abbott Laboratories | $96.29 | 2019 | |
| Intuitive Surgical, INC. | $84.43 | 2022 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xiang Dong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.